

TRADE/2321 - Meeting with US Chamber

Meeting date and place

Meeting held on 05/05/2022 10:00

Participating organisation(s) representative(s)

Art.4(1)(b)	Bayer AG	Participant
Art.4(1)(b)	Pfizer Inc.	Participant
Art.4(1)(b)	Eli Lilly and Company	Participant
Art.4(1)(b)	QUALCOMM Incorporated	Participant
Art.4(1)(b)	Global Innovation Policy Center	Participant, Requester
Art.4(1)(b)	Biotechnology Innovation Organization	Participant
Art.4(1)(b)	Advanced medical technology association	Participant
Art.4(1)(b)	MSD (Europe), Inc. (Merck Sharp & Dohme)	Participant
Art.4(1)(b)	Pharmaceutical Research and Manufacturers of America	Participant
Art.4(1)(b)	Pharmaceutical Research and Manufacturers of America	Participant

Main issues discussed

At the request of the US Chamber and its members, the Commission presented the state of play of the talks in the WTO with regard to the proposal for a waiver of IP rights with regard to COVID-19 products. The US Chamber members presented their general concerns with the waiver proposal as endangering the ongoing research and innovation into COVID-19 and other therapies as well as the ongoing collaborations. The US Chamber members also enquired about the state of play with the WTO

case against China regarding the standard essential patents. The Commission explained the state of play on this matter

Directorate or unit

TRADE.B.3

Internal participants

Art.4(1)(b)	TRADE B/3	Art.4(1)(b) @ec.europa.eu)	Notetaker, Participant
Art.4(1)(b)	TRADE B/3	Art.4(1)(b) @ec.europa.eu)	Notetaker, Participant

Author(s) of minutes

Art.4(1)(b)

Validator and validation date

Art.4(1)(b)